The critical role of continous improvement in parenteral drug manufacturing

Read the news

Brochure describing Grifols Partnership services, products and capabilities offered to pharmaceutical companies. Featuring two FDA approved Manufacturing sites

Growth in the pharmaceutical industry is no longer exclusively driven by large pharmaceutical companies. The switch in the marketplace from a focus on blockbuster drugs to an emphasis on therapies that treat orphan and rare diseases has led to the rise of small and emerging pharma companies founded to advance novel medicines for specialized patient populations. These innovators require the support of contract service providers that recognize their unique requirements.

Drug candidates are becoming increasingly complex as manufacturers continue to focus on niche and personalized medicines. Contract development and manufacturing organizations with process and capacity, flexibility, and wide-ranging expertise in small-volume GMP manufacturing are needed to support efforts by pharma companies to rapidly bring these specialized products to the market.

Demand for parenteral drugs continues to increase as the overall drug market expands and new therapies for both chronic and rare diseases enter the pipeline. Manufacturers are faced with increasing complexity, not only because of the drug substances, but also due to formulations, patient-centric delivery technologies,and regulatory requirements, which are all further complicated by abbreviated development timelines.

Extensive process understanding is required to ensure the consistent manufacture of high-quality sterile parenteral products. At Grifols, our use of state-of-the-art automated aseptic processing systems, including form-fill-seal (FFS) technology, ensures control with minimal human intervention.

Marga Viñes talks extensively about Grifols Partnershp's CDMO services.

Read Pharma’s Almanac exclusive interview with Oriol Prat, Oriol Argemí and Marga Viñes, regarding trends in parenteral manufacturing, and how Grifols is maintaining its leadership in the small-volume parenteral manufacturing market.

Watch Pharma’s Almanac exclusive interview with Oriol Prat, Oriol Argemí and Marga Viñes, about trends in parenteral manufacturing, and how Grifols is maintaining its leadership in the small-volume parenteral manufacturing market.

Combining the focus on parenteral with the expertise of an established pharmaceutical leader, the contract manufacturing business is agile and flexible in its service to companies outsourcing the development and manufacture of added value injectable drugs.

Have you ever wondered what Grifols sites around the world are like? This aerial tour video provides a great visual perspective of various sites. Take two and a half minutes to watch it and see our sites around the world.

Michael Howell, Site Director of Albumin Manufacturing at Grifols, speaks with Nigel Walker about how Grifols’ state-of-the-art facility in Dublin meets client demands in this new era in healthcare. They also discuss how risk assessment plays a major role in Grifols' success with customers.

Our customers are happy customers! See what they say about our contract manufacturing services and what is like to trust their project in us!